On May 8, 2019 Complix, a biopharmaceutical company developing Cell Penetrating Alphabodies (CPABs) to target intracellular disease targets, reported that its Chief Executive Officer, Dr Mark Vaeck, will be presenting at the 20th Annual BioEquity Europe Conference in Barcelona, Spain, May 20-21 (Press release, Complix, MAY 8, 2019, View Source [SID1234535932]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In his presentation on Dr Vaeck will provide an overview of Complix’ recent achievements in applying its CPAB platform to develop next-generation therapeutics acting on important but intractable intracellular targets.

The presentation will take place on Monday May 20th at 16.50h CET in room Vivaldi 1 of the Crown Plaza Barcelona Fira Center Hotel.